3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Precancerous Conditions
1
Polycystic Ovary Syndrome
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Hemangioma, Cavernous, Central Nervous System
1
Heart Failure
1
Interventions
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hemangioma, Cavernous, Central Nervous System
×
Atorvastatin
×
Clear all
NCT02603328
2025-08-22
AT CASH EPOC
University of Chicago
Phase 1/2
Completed
80 enrolled
19 charts